In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mindray Makes Subtle Move Into Orthopedics

Executive Summary

China’s international medical device leader Mindray Medical International Ltd. entered the rough-and-tumble Chinese orthopedics industry. The company accquired a controlling stake in Wuhan Dragonbio Surgical Implant Co. Ltd., a small China-based supplier of trauma, large joint and spine products. The purchase pits Mindray – which sells large durable medical equipment across the globe ( against larger China-based companies like China Kanghui Holdings, Shandong Weigao Group Medical Polymer Co. Ltd. and Trauson Medical Instrument Co. Ltd., as well as multinationals. Dragonbio is a bit player in the Chinese orthopedics market. But Mindray ( which is projected to report $1 billion in sales this year – likely won’t be content with that place on the pecking order.

You may also be interested in...



Pipeline Watch: Japan Dominates 25 New Approvals, Plus Six Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

What’s Next? Five Things To Look Out For In October

A busy October will include planned biosimilar launches and key appointments for the off-patent sector.

Sandoz: Big Cap Biosimilar Rivals Lack Clarity On Commitment

Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV003871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel